Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.
The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.
Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.
Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.
This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.
Can-Fite BioPharma announced that its veterinary partner, Vetbiolix, has initiated a safety and efficacy study of Piclidenoson for treating canine osteoarthritis, targeting a market expected to reach
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, at 12:30 PM ET. The presentation will emphasize Can-Fite's advanced-stage pipeline, including a Phase III study in psoriasis with results expected in Q1 2022. Upcoming studies include a Phase II study in NASH and a pivotal Phase III trial in liver cancer. Can-Fite is focused on developing proprietary drugs for inflammatory diseases, cancer, and liver conditions, including the candidates Piclidenoson and Namodenoson.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present research on the CBD Rich T3/C15 cannabis fraction at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting from November 12-15, 2021. The study indicates that this cannabis fraction inhibits the growth of HEP-3b hepatocellular carcinoma cells via the A3 Adenosine Receptor. This inhibitory activity suggests potential therapeutic applications in liver cancer treatment.
Can-Fite BioPharma (NYSE: CANF) announced the granting of a patent for its NASH drug candidate, Namodenoson, in Hong Kong and Mexico, with a notice of allowance in Japan. This patent enhances Can-Fite's intellectual property in treating ectopic fat accumulation related to NAFLD and NASH, projected to reach a $35 billion market by 2025. Namodenoson has successfully completed a Phase IIa study and is currently in Phase IIb trials. The company has secured about $20 million in non-dilutive payments for Namodenoson across multiple regions.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 5th Annual Antifibrotic Drug Development Summit on November 3, 2021. Her presentation will highlight innovative strategies for promoting tissue regeneration, focusing on clinical trial data for Namodenoson, which showed a dose-dependent reduction in liver fat and fibrosis in a Phase IIa study. The Phase IIb study is currently approved and underway, while Can-Fite continues to advance its clinical pipeline in cancer and liver diseases.
Can-Fite BioPharma Ltd (NYSE: CANF) announced the publication of a study on Namodenoson for treating non-alcoholic fatty liver disease (NASH) in the journal Alimentary Pharmacology & Therapeutics. The Phase IIa trial met its endpoints, showcasing significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects. A Phase IIb trial is set to enroll patients in Q4 2021. The market for NASH treatments is projected to reach $35-40 billion by 2025. With no current U.S. approved drugs for NASH, the potential for Namodenoson is substantial.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the NASH Investor Conference on
Can-Fite BioPharma Ltd. (NYSE American: CANF) will have CEO Dr. Pnina Fishman present at the Benzinga Healthcare Small Cap Conference on September 29, 2021.
The presentation will include a panel discussion on medical cannabis and insights into Can-Fite’s drug development efforts, including ongoing trials for Piclidenoson and Namodenoson targeting psoriasis and liver cancer. With FDA designations for Namodenoson, Can-Fite aims to capture significant market opportunities in the pharmaceutical industry.
Can-Fite BioPharma Ltd (NYSE American: CANF) has secured approximately
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the company's proprietary small molecule drugs aimed at inflammatory, cancer, and liver diseases, with a special emphasis on Piclidenoson and Namodenoson, which are advancing through various clinical trials. The presentation will be available on the conference portal at 7:00 AM ET on September 13.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. (CANF)?
What does Can-Fite BioPharma Ltd. specialize in?
Where is Can-Fite BioPharma Ltd. located?
What is Piclidenoson?
What is Namodenoson used for?
What stage are the trials for Namodenoson?
What is the A3 adenosine receptor (A3AR)?
How does Can-Fite BioPharma's technology benefit patients?
What is the significance of Can-Fite BioPharma's partnerships?
Is Can-Fite BioPharma listed on any stock exchange?
What is the focus of Can-Fite BioPharma's current projects?
